Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug IBI3014 takes on advanced solid tumors in first human trial

NCT ID NCT06974812

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 30, 2026 · Last updated Jun 15, 2026 · Updated 19 times

Summary

This study tests a new drug called IBI3014 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 250 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian cancer hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanghai Pulmonary Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200433, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

UNRESECTABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS